Loading
LIV-1 is an oestrogen-regulated zinc transporter on most breast cancers; the ADC against it (ladiratuzumab vedotin) showed activity in triple-negative disease but was discontinued in 2024.
LIV-1 is expressed in >90% of breast cancers including ~70% of TNBC, and in prostate, melanoma and cervical cancers. Ladiratuzumab vedotin (SGN-LIV1A, MMAE payload) produced ~25-30% responses in pretreated metastatic breast cancer and was tested with pembrolizumab; Pfizer discontinued it in 2024 after acquiring Seagen. The target remains validated for next-generation ADCs and radioligands.
In plain words · LIV-1 is an oestrogen-regulated zinc transporter on most breast cancers; the ADC against it (ladiratuzumab vedotin) showed activity in triple-negative disease but was discontinued in 2024.
LIV-1 is an oestrogen-regulated zinc transporter on most breast cancers; the ADC against it (ladiratuzumab vedotin) showed activity in triple-negative disease but was discontinued in 2024.
Zinc transporter of the ZIP family (SLC39A6) that localises to the plasma membrane, imports zinc and promotes EMT via STAT3/Snail; transcriptionally induced by oestrogen (hence LIV-1, from ER+ breast cancer lines).
No product in this corpus aims at LIV-1 (SLC39A6) yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
First described 2001. Earliest sequence paper UniProt cites for the protein: Green et al, 2001. Source.
Zinc transporter of the ZIP family (SLC39A6) that localises to the plasma membrane, imports zinc and promotes EMT via STAT3/Snail; transcriptionally induced by oestrogen (hence LIV-1, from ER+ breast cancer lines).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| HR-positive / HER2-negative breast cancer | 37-43% | IHC, high SLC39A6 expression (cytoplasmic H-score >160 in 37%; nuclear staining in 43%) in 670 unselected early breast cancers, enriched in ER+ tumours | Assay- and cutoff-dependent: Seagen's SGN-LIV1A programme reported far higher any-expression rates with its own IHC assay | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"LIV-1" OR ABSTRACT:"LIV-1" OR TITLE:"SLC39A6" OR ABSTRACT:"SLC39A6") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LIV-1 (SLC39A6), not a curated reading list.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC).
Shares Pfizer (incl. Seagen), HR-positive / HER2-negative breast cancer, Prostate cancer.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC).
Shares Pfizer (incl. Seagen), HR-positive / HER2-negative breast cancer.
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC).
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC).
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC).
Shares Pfizer (incl. Seagen), Antibody-drug conjugate (ADC).